IP Library Granted Patent US 8,025,897
Granted Patent B2
US 8,025,897 · App. 11/423,550 · Granted Sep 27, 2011

Ibuprofen composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,025,897
App. No.
11/423,550
Granted
Sep 27, 2011
Kind
B2
Abstract

Fumaric acid is added in amounts sufficient to reduce the burn sensation commonly associated with propionic acid derivatives.

Claims (7)

1. An orally administered composition comprising a therapeutically effective amount of a racemic mixture of a propionic acid derivative selected from the group consisting of ibuprofen, naproxen, benoxaprofen, naproxen sodium, flurbiprofen, fenoprofen, fenbuprofen, ketoprofen, indoprofen, pirprofen, carpofen, oxaprofen, pranoprofen, microprofen, tioxaprofen, suproprofen, alminoprofen, tiaprofenic acid, fluprofen, bucloxic acid and their salts thereof, wherein the composition contains from about 50 to about 150 weight percent fumaric acid based upon the weight of the racemic mixture of the propionic acid derivative, the propionic acid derivative provided as a plurality of particles coated with a hydrocolloid; provided that no fumaric acid is incorporated in the hydrocolloid coating on the particles or granules of the propionic acid derivative, and wherein the level of the fumaric acid is from about 7% to about 13% by weight of the total composition weight.

2. The orally administered composition of claim 1 , wherein the hydrocolloid material is less than about 5 weight percent of the total composition weight.

3. The orally administered composition of claim 1 , wherein the racemic mixture of the propionic acid derivative is ibuprofen.

4. The orally administered composition of claim 1 , wherein the fumaric acid and the racemic mixture of the propionic acid derivative are provided in a tablet.

5. The orally administered composition of claim 1 , wherein the composition is in the form of a chewable dosage form.

6. The orally administered composition of claim 1 , wherein the composition is in the form of a semi-solid.

7. The orally administered composition of claim 1 , wherein the composition is in the form of a suckable solid.

Assignments (1)
MERGER AND CHANGE OF NAME Recorded Jul 2, 2015
From: MCNEIL-PPC, INC.; JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 036049/0254 →